Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
03 août 2023 16h01 HE
|
Collegium Pharmaceutical, Inc.
– Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2’23 GAAP Net Income of $13.0 Million – – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has...
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
20 juil. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Participate in Jefferies Healthcare Conference
01 juin 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports First Quarter 2023 Financial Results
04 mai 2023 16h01 HE
|
Collegium Pharmaceutical, Inc.
– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca® and Xtampza® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance...
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
20 avr. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
23 févr. 2023 16h01 HE
|
Collegium Pharmaceutical, Inc.
– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference...
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
22 févr. 2023 08h00 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its...
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
07 févr. 2023 21h54 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875%...
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
06 févr. 2023 16h08 HE
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000...